Safety and Tolerability of CDX-6114 in Healthy Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a Phase 1, double‐blind, placebo‐controlled study in approximately 32 healthy volunteers who are 18 to 55 years old. Four cohorts are planned, each consisting of 8 subjects; the cohorts as planned are 0.225, 0.75, 2.25, and 7.5 g in oral solution. Increasing doses of CDX‐6114 will be assessed sequentially until the final dose is evaluated or any of the stopping criteria are reached. Subjects will each receive a single dose and then will be followed for a total of 22 days (3 weeks).
Epistemonikos ID: 953a8e6863e53b3317c4b6114dce5478516ea715
First added on: May 21, 2024